SCHEMBL4412181

SCHEMBL4412181

CCOC(=O)CNCCNS(=O)(=O)c1nnc(-c2ccc(Cl)cc2[N+](=O)[O-])s1

nearest known ligand 0.39

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.39
MEN1 O00255 3/20 0.39
MAPT P10636 7/20 0.37
ALDH1A1 P00352 3/20 0.37
KDM4E B2RXH2 1/20 0.37
POLB P06746 2/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
LMNA P02545 3/20 0.37
HTT P42858 1/20 0.37
NPSR1 Q6W5P4 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
PDE7A Q13946 1/20 0.36
THRB P10828 1/20 0.35
PKM P14618 2/20 0.35
KCNMA1 Q12791 1/20 0.35
MCL1 Q07820 1/20 0.34
MAPK1 P28482 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4411288 0.88 DDX3X (0.42) MAPTALDH1A1KDM4ESMN1; SMN2LMNA
SCHEMBL4413837 0.88 MAPT (0.45) KMT2AMEN1MAPTALDH1A1KDM4E
SCHEMBL4418426 0.86 KMT2A (0.42) KMT2AMEN1MAPTKDM4EPOLB
SCHEMBL4413761 0.82 MAPT (0.41) KMT2AMEN1MAPTALDH1A1KDM4E
SCHEMBL27636808 0.81 ALDH1A1 (0.34) KMT2AMEN1MAPTALDH1A1KDM4E
SCHEMBL3815831 0.81 MAPT (0.44) KMT2AMEN1MAPTALDH1A1KDM4E
SCHEMBL4412465 0.81 CSNK2A2 (0.47) KMT2AMEN1MAPTALDH1A1SMN1; SMN2
SCHEMBL4426611 0.77 ALDH1A1 (0.33) KMT2AMEN1ALDH1A1
SCHEMBL6458867 0.77 MAPT (0.43) KMT2AMEN1MAPTALDH1A1KDM4E
SCHEMBL4418662 0.76 LTA4H (0.43) ALDH1A1KDM4ESMN1; SMN2PKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1829714-B Pna monomer and precursor PANAGENE INC 2012-05-30 CN disclosed
EP-1651642-B1 PNA MONOMER AND PRECURSOR PANAGENE INC (KR) 2009-11-04 EP disclosed
US-7211668-B2 PNA monomer and precursor PANAGENE, INC. (KR) 2007-05-01 US disclosed
EP-1651642-A4 PNA MONOMER AND PRECURSOR PANAGENE INC (KR) 2006-11-29 EP disclosed
CN-1829714-A PNA monomer and precursor PANAGENE INC (KR) 2006-09-06 CN disclosed
EP-1651642-A1 PNA MONOMER AND PRECURSOR Panagene Inc. (KR) 2006-05-03 EP disclosed
US-20050026930-A1 PNA monomer and precursor PANAGENE, INC. (KR) 2005-02-03 US disclosed
WO-2005009998-A1 PNA MONOMER AND PRECURSOR PANAGENE INC. (US) 2005-02-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050026930-A1 PNA monomer and precursor RNGTT, POLL, NSUN3 KMT2A 4464/4885MEN1 1967/4885MAPT 4633/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.